NeuroDiscovery makes market debut
Monday, 15 August, 2005
Perth-based neurology-focused biotech company NeuroDiscovery (ASX:NDL) listed today on the Australian Stock Exchange at AUD$0.21, one cent above its issue price of $0.20.
NeuroDiscovery's IPO raised AUD$1.5 million through the issue of 36 million shares, and the company has finalised purchase of UK-based NeuroSolutions, which has a mature pipeline of programs for the treatment of pain.
"We are very pleased that we have been able to buy NeuroSolutions and welcome the University of Warwick as our major shareholder. As this is the first successful spin-out of the university we look forward to working with them in the next few years." said NeuroDiscovery chairman David McAuliffe.
At the time of writing, shares were trading at $0.20.
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
